Kibow Pharmaceuticals Announces Completion of First Patient in Phase II, 6 Months RCT of US-APR2020 and Enrollment in Subsequent 6 Months Open-Label Trial, a Unique Design of a Best-in-Class Add-on Treatment for Chronic Kindy Disease Patients

Kibow Pharmaceuticals LLC is a phase 2/3 clinical-stage company focused on developing novel live biotherapeutic products (LBP) for chronic kidney disease (CKD) patients. Kibow’s first clinical product, US-APR2020, is in a phase 2b multi-site global clinical trial and has recruited about half of the targeted 630 CKD stage 4 subjects since October 2021 (details on […]

We use cookies

We use cookies to improve your experience on this website. You may choose which types of cookies to allow and change your preferences at any time. Disabling cookies may impact your experience on this website. You can learn more by viewing our Cookie Policy.